All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On 2nd January 2018, SeattleGenetics announced in a press release that the U.S. food and drug administration (FDA) has accepted a supplemental Biologics License Application (BLA) for brentuximab vedotin (Adcetris®) in combination with chemotherapy for the frontline treatment of patients with advanced classical Hodgkin lymphoma (HL).
The FDA decision was based on clinical trial results of the ECHELON-1 study that were presented at the 59th ASH Annual Meeting and Exhibition in Atlanta, GA, December 2017. The phase III study was international, open-label, randomized and multicenter and compared brentuximab vedotin plus AVD (doxorubicin, vinblastine, and dacarbazine) with ABVD as frontline therapy in patients with stage III or IV classic Hodgkin’s lymphoma. The trial results showed that A+AVD had significantly superior modified progression-free survival.
In an interview at the ASH annual meeting 2017 with Anas Younes, University Professor at the Weill-Cornell Medical College, he noted that "for North America ABVD is still the standard of care," and that alternative options may be limited. He added that "having a new option with brentuximab plus AVD is a good step forward but still more work needs to be done."
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox